Symbols / TVGN
TVGN Chart
About
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment. It is also developing TVGN 920 which is in preclinical trial for treating cervical cancer; TVGN 960 which is in preclinical trial for treating oropharyngeal cancer; TVGN 601 which is in preclinical trial for treating multiple sclerosis; TVGN 930 which is in preclinical trial for treating Epstein-Barr virus associated lymphomas; and TVGN 116 a product candidate targeted at hepatitis B and is in preclinical trial. Tevogen Bio Holdings Inc. was formerly known as Tevogen Bio Inc. and changed its name to Tevogen Bio Holdings Inc. in February 2024. The company was founded in 2020 and is headquartered in Warren, New Jersey.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 55.92M |
| Enterprise Value | 69.45M | Income | -31.42M | Sales | — |
| Book/sh | -0.08 | Cash/sh | 0.01 | Dividend Yield | — |
| Payout | 0.00% | Employees | 18 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | -3.30 | P/C | — |
| EV/EBITDA | -2.26 | EV/Sales | — | Quick Ratio | 0.18 |
| Current Ratio | 0.32 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -0.18 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2026-03-31 | ROA | -4.40% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 201.52M |
| Shs Float | 27.85M | Short Float | 4.23% | Short Ratio | 3.25 |
| Short Interest | — | 52W High | 1.51 | 52W Low | 0.23 |
| Beta | -0.78 | Avg Volume | 913.34K | Volume | 79.21K |
| Target Price | $5.00 | Recom | None | Prev Close | $0.27 |
| Price | $0.28 | Change | 1.80% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$5.00
Mean price target
2. Current target
$0.28
Latest analyst target
3. DCF / Fair value
$-0.07
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.28
Low
$5.00
High
$5.00
Mean
$5.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-20 | main | D. Boral Capital | Buy → Buy | $5 |
| 2025-09-04 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-08-18 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-08-06 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-08-04 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-06-18 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-06-10 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-05-27 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-05-12 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-04-29 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-04-21 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-11 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-03-04 | init | D. Boral Capital | — → Buy | $10 |
- Tevogen board weighs one-time special dividend tied to future targets - Stock Titan Fri, 30 Jan 2026 08
- Analysts Expect Breakeven For Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Before Long - Yahoo Finance ue, 09 Dec 2025 08
- Insider Sellers Might Regret Selling Tevogen Bio Holdings Shares at a Lower Price Than Current Market Value - simplywall.st Wed, 12 Nov 2025 08
- Tevogen Bio Announces Modification to Long-Term Stock Incentive Program to Align Awards with Company Milestones - Quiver Quantitative hu, 29 Jan 2026 08
- Tevogen (Nasdaq: TVGN) on NJBIZ Power List with $18–22B outlook, NJ expansion - Stock Titan Mon, 08 Dec 2025 08
- Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue - GlobeNewswire hu, 29 Jan 2026 08
- Tevogen Bio Holdings receives Nasdaq notice for minimum bid price deficiency - Investing.com Fri, 26 Sep 2025 07
- Tevogen Bio Explores Potential One-Time Special Cash Dividend - TipRanks Fri, 30 Jan 2026 08
- Tevogen Bio Holdings Inc. Secures $50 Million Agreement with CD8 Technology Services to Enhance R&D and Manufacturing Capabilities - Nasdaq Mon, 28 Apr 2025 07
- Tevogen Bio Holdings Inc. (NASDAQ:TVGN): Are Analysts Optimistic? - Yahoo Finance Wed, 02 Jul 2025 07
- Tevogen Bio Holdings: Initiating Sell Rating Based On Pipeline Uncertainty And Cash Constraints - Seeking Alpha Fri, 11 Apr 2025 07
- Tevogen Bio Holdings Inc. Recognized in 2025 New Jersey Power List for Innovation and Economic Impact - Quiver Quantitative Mon, 08 Dec 2025 08
- Tevogen Bio Holdings Inc. (NASDAQ:TVGN): Is Breakeven Near? - simplywall.st hu, 08 Jan 2026 08
- Biotech Tevogen now links worker stock rewards to hitting revenue goals - Stock Titan hu, 29 Jan 2026 08
- Tevogen Bio (Nasdaq: TVGN) ties Dr. Patton's Yale role to $1 billion forecasts - Stock Titan ue, 09 Dec 2025 08
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 50000 | — | — | Stock Gift at price 0.00 per share. | SAADI RYAN H | Chief Executive Officer | — | 2025-12-18 00:00:00 | D |
| 1 | 460000 | — | — | Stock Gift at price 0.00 per share. | SAADI RYAN H | Chief Executive Officer | — | 2025-12-11 00:00:00 | D |
| 2 | 300000 | — | — | Stock Gift at price 0.00 per share. | DESAI KIRTI | Chief Financial Officer | — | 2025-12-11 00:00:00 | D |
| 3 | 20000 | — | — | Stock Gift at price 0.00 per share. | SAADI RYAN H | Chief Executive Officer | — | 2025-08-15 00:00:00 | D |
| 4 | 200000 | — | — | Stock Award(Grant) at price 0.00 per share. | KHAN SADIQ | Officer | — | 2025-06-27 00:00:00 | D |
| 5 | 8000000 | — | — | Stock Award(Grant) at price 0.00 per share. | SAADI RYAN H | Chief Executive Officer | — | 2025-06-27 00:00:00 | D |
| 6 | 750000 | — | — | Stock Award(Grant) at price 0.00 per share. | DESAI KIRTI | Chief Financial Officer | — | 2025-06-27 00:00:00 | D |
| 7 | 300000 | — | — | Stock Award(Grant) at price 0.00 per share. | FLOMENBERG NEAL | Officer | — | 2025-06-27 00:00:00 | D |
| 8 | 1438206 | 1768993 | — | Sale at price 1.23 per share. | SAADI RYAN H | Chief Executive Officer | — | 2025-06-09 00:00:00 | D |
| 9 | 232968 | 253935 | — | Sale at price 1.09 per share. | FLOMENBERG NEAL | Officer | — | 2025-03-12 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 1.13M | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.21 | 0.00 |
| NormalizedEBITDA | -4.69M | -58.89M | -953.08K | -14.99M |
| TotalUnusualItems | -8.45M | 0.00 | 5.36M | |
| TotalUnusualItemsExcludingGoodwill | -8.45M | 0.00 | 5.36M | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -13.73M | -60.48M | 4.41M | -15.60M |
| ReconciledDepreciation | 403.58K | 378.36K | 230.82K | 9.38K |
| EBITDA | -13.14M | -58.89M | 4.41M | -14.99M |
| EBIT | -13.54M | -59.27M | 4.41M | -15.00M |
| NetInterestIncome | -184.04K | -1.21M | 0.00 | -598.50K |
| InterestExpense | 184.04K | 1.21M | 0.00 | 598.50K |
| NormalizedIncome | -5.28M | -60.48M | 172.82K | -15.60M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -13.73M | -60.48M | 4.41M | -15.60M |
| TotalExpenses | 53.56M | 8.84M | 953.08K | 4.62M |
| TotalOperatingIncomeAsReported | -53.56M | -8.84M | -13.72M | -4.62M |
| DilutedAverageShares | 146.67M | 165.42M | 120.00M | 120.00M |
| BasicAverageShares | 146.67M | 165.42M | 120.00M | 120.00M |
| DilutedEPS | -0.07 | -0.38 | 0.04 | -0.13 |
| BasicEPS | -0.07 | -0.38 | 0.04 | -0.13 |
| DilutedNIAvailtoComStockholders | -13.73M | -60.48M | 4.41M | -15.60M |
| NetIncomeCommonStockholders | -13.73M | -60.48M | 4.41M | -15.60M |
| NetIncome | -13.73M | -60.48M | 4.41M | -15.60M |
| NetIncomeIncludingNoncontrollingInterests | -13.73M | -60.48M | 4.41M | -15.60M |
| NetIncomeContinuousOperations | -13.73M | -60.48M | 4.41M | -15.60M |
| PretaxIncome | -13.73M | -60.48M | 4.41M | -15.60M |
| OtherIncomeExpense | 40.02M | -50.43M | 5.36M | -10.38M |
| OtherNonOperatingIncomeExpenses | 48.47M | -50.43M | -7.38M | -10.38M |
| SpecialIncomeCharges | -7.50M | 0.00 | 0.00 | |
| WriteOff | 250.00K | 0.00 | ||
| RestructuringAndMergernAcquisition | 7.50M | 0.00 | ||
| GainOnSaleOfSecurity | -948.18K | 2.71M | 5.36M | |
| NetNonOperatingInterestIncomeExpense | -184.04K | -1.21M | 0.00 | -598.50K |
| InterestExpenseNonOperating | 184.04K | 1.21M | 0.00 | 598.50K |
| OperatingIncome | -53.56M | -8.84M | -953.08K | -4.62M |
| OperatingExpense | 53.56M | 8.84M | 953.08K | 4.62M |
| ResearchAndDevelopment | 31.03M | 4.40M | 5.77M | 2.96M |
| SellingGeneralAndAdministration | 22.53M | 4.44M | 953.08K | 1.66M |
| GeneralAndAdministrativeExpense | 22.53M | 4.44M | 953.08K | 1.66M |
| OtherGandA | 7.05M | 3.34M | 953.08K | 898.09K |
| SalariesAndWages | 15.48M | 1.10M | 5.80M | 764.52K |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 177.99M | 165.42M | 158.11M | 158.11M |
| ShareIssued | 177.99M | 165.42M | 158.11M | 158.11M |
| NetDebt | 1.37M | 93.88M | 33.81M | 16.36M |
| TotalDebt | 2.89M | 95.42M | 40.01M | 23.48M |
| TangibleBookValue | -15.47M | -94.43M | 342.08M | -16.49M |
| InvestedCapital | -12.82M | 503.10K | 342.08M | 6.99M |
| WorkingCapital | -6.68M | -83.76M | -76.10K | 6.51M |
| NetTangibleAssets | -6.67M | -94.43M | 342.08M | -16.49M |
| CapitalLeaseObligations | 234.86K | 487.57K | 710.93K | 0.00 |
| CommonStockEquity | -15.47M | -94.43M | 342.08M | -16.49M |
| PreferredStockEquity | 8.80M | |||
| TotalCapitalization | -5.67M | -80.21M | 342.08M | 6.99M |
| TotalEquityGrossMinorityInterest | -6.67M | -94.43M | 342.08M | -16.49M |
| StockholdersEquity | -6.67M | -94.43M | 342.08M | -16.49M |
| RetainedEarnings | -113.39M | -99.66M | -14.78M | -17.14M |
| AdditionalPaidInCapital | 97.89M | 5.22M | 5.17M | 586.23K |
| CapitalStock | 8.82M | 12.00K | 356.87M | 63.88K |
| CommonStock | 17.80K | 12.00K | 356.87M | 63.88K |
| PreferredStock | 8.80M | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 10.14M | 99.93M | 15.06M | 24.15M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 1.09M | 14.45M | 14.71M | 23.48M |
| DerivativeProductLiabilities | 87.18K | 0.00 | 7.25K | |
| NonCurrentDeferredLiabilities | 14.70M | 14.70M | ||
| LongTermDebtAndCapitalLeaseObligation | 1.01M | 14.45M | 39.73M | 23.48M |
| LongTermCapitalLeaseObligation | 5.80K | 234.86K | 432.73K | 0.00 |
| LongTermDebt | 1.00M | 14.22M | 39.30M | 23.48M |
| CurrentLiabilities | 9.04M | 85.48M | 350.45K | 667.94K |
| OtherCurrentLiabilities | 403.23K | 120.15K | 237.60K | 45.27K |
| CurrentDebtAndCapitalLeaseObligation | 1.88M | 80.96M | 278.21K | |
| CurrentCapitalLeaseObligation | 229.06K | 252.71K | 278.21K | 0.00 |
| CurrentDebt | 1.65M | 80.71M | ||
| OtherCurrentBorrowings | 80.71M | |||
| CurrentNotesPayable | 1.65M | 0.00 | ||
| PayablesAndAccruedExpenses | 6.76M | 4.39M | 350.45K | 622.68K |
| CurrentAccruedExpenses | 1.31M | 976.30K | 578.77K | 244.68K |
| Payables | 5.45M | 3.42M | 350.45K | 378.00K |
| DuetoRelatedPartiesCurrent | 250.00K | 0.00 | 140.00K | |
| AccountsPayable | 5.20M | 3.42M | 210.45K | 378.00K |
| TotalAssets | 3.46M | 5.51M | 357.14M | 7.66M |
| TotalNonCurrentAssets | 1.10M | 3.78M | 356.86M | 485.27K |
| OtherNonCurrentAssets | 575.84K | 271.14K | 356.86M | 342.65K |
| NonCurrentDeferredAssets | 0.00 | 2.58M | ||
| NetPPE | 524.93K | 928.51K | 1.31M | 142.62K |
| AccumulatedDepreciation | -425.33K | -263.12K | -99.82K | -9.38K |
| GrossPPE | 950.26K | 1.19M | 1.41M | 152.00K |
| Leases | 263.22K | 263.22K | 263.22K | 0.00 |
| OtherProperties | 228.49K | 469.86K | 684.92K | |
| MachineryFurnitureEquipment | 458.55K | 458.55K | 458.55K | 152.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 2.36M | 1.72M | 274.36K | 7.17M |
| OtherCurrentAssets | 919.09K | 670.58K | 145.17K | 53.96K |
| Receivables | 158.82K | 0.00 | 0.00 | |
| DuefromRelatedPartiesCurrent | 158.82K | 0.00 | 0.00 | |
| CashCashEquivalentsAndShortTermInvestments | 1.28M | 1.05M | 129.19K | 7.12M |
| CashAndCashEquivalents | 1.28M | 1.05M | 129.19K | 7.12M |
| CashFinancial | 1.28M | 1.05M | 129.19K | 7.12M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -12.00M | -8.30M | -215.40K | -5.38M |
| RepurchaseOfCapitalStock | -342.98M | 0.00 | ||
| IssuanceOfDebt | 1.00M | 4.00M | 0.00 | 12.50M |
| IssuanceOfCapitalStock | 11.00M | 0.00 | ||
| CapitalExpenditure | -133.00K | -479.04K | -109.73K | |
| EndCashPosition | 1.28M | 1.05M | 129.19K | 7.12M |
| BeginningCashPosition | 1.05M | 5.48M | 344.58K | 3.84K |
| ChangesInCash | 230.60K | -4.43M | -215.40K | 7.12M |
| FinancingCashFlow | 12.23M | 3.87M | 0.00 | 12.50M |
| CashFlowFromContinuingFinancingActivities | 12.23M | 3.87M | 0.00 | 12.50M |
| NetOtherFinancingCharges | 229.33K | -127.75K | ||
| NetPreferredStockIssuance | 11.00M | 0.00 | ||
| PreferredStockIssuance | 11.00M | 0.00 | ||
| NetCommonStockIssuance | -342.98M | 0.00 | ||
| CommonStockPayments | -342.98M | 0.00 | ||
| NetIssuancePaymentsOfDebt | 1.00M | 4.00M | 0.00 | 12.50M |
| NetShortTermDebtIssuance | 1.32M | 0.00 | ||
| ShortTermDebtIssuance | 1.32M | 0.00 | ||
| NetLongTermDebtIssuance | 1.00M | 4.00M | 0.00 | 12.50M |
| LongTermDebtIssuance | 1.00M | 4.00M | 0.00 | 12.50M |
| InvestingCashFlow | 0.00 | -133.00K | 0.00 | -109.73K |
| CashFlowFromContinuingInvestingActivities | 0.00 | -133.00K | 0.00 | -109.73K |
| NetOtherInvestingChanges | 342.92M | |||
| NetPPEPurchaseAndSale | 0.00 | -133.00K | -479.04K | -109.73K |
| PurchaseOfPPE | 0.00 | -133.00K | -479.04K | -109.73K |
| OperatingCashFlow | -12.00M | -8.17M | -215.40K | -5.27M |
| CashFlowFromContinuingOperatingActivities | -12.00M | -8.17M | -215.40K | -5.27M |
| ChangeInWorkingCapital | -5.49K | 293.20K | 737.69K | -1.25M |
| ChangeInOtherCurrentLiabilities | -252.71K | -223.36K | -114.37K | 0.00 |
| ChangeInOtherCurrentAssets | -511.01K | 323.74K | -252.24K | -342.65K |
| ChangeInPayablesAndAccruedExpense | 1.00M | 510.43K | 291.08K | -852.33K |
| ChangeInAccruedExpense | -681.45K | -603.83K | 568.70K | 240.27K |
| ChangeInPayable | 1.69M | 1.11M | 291.08K | -1.09M |
| ChangeInAccountPayable | 1.69M | 1.11M | 171.08K | -1.09M |
| ChangeInPrepaidAssets | -246.00K | -317.61K | 446.61K | -53.96K |
| ChangeInReceivables | -267.00K | 0.00 | ||
| OtherNonCashItems | -39.49M | 51.63M | 8.32M | 10.98M |
| StockBasedCompensation | 40.76M | 0.00 | 4.58M | 582.41K |
| UnrealizedGainLossOnInvestmentSecurities | -2.73M | -4.95M | ||
| AssetImpairmentCharge | 250.00K | |||
| DepreciationAmortizationDepletion | 403.58K | 378.36K | 230.82K | 9.38K |
| DepreciationAndAmortization | 403.58K | 378.36K | 230.82K | 9.38K |
| Depreciation | 403.58K | 378.36K | 230.82K | 9.38K |
| OperatingGainsLosses | 58.18K | 21.75K | -413.25K | |
| GainLossOnInvestmentSecurities | 58.18K | 21.75K | -413.25K | |
| NetIncomeFromContinuingOperations | -13.73M | -60.48M | 4.41M | -15.60M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TVGN
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|